Visit the Wayland Group Corporation Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Maricann Group Inc. Receives Export Permit From Health Canada
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCMKTS:MRRCF) (“Maricann” or “the Company”), is pleased to announce that on Friday April13th, 2018, its wholly owned subsidiary, Maricann Inc. received an export permit from Health Canada for a shipment of dried cannabis flower to Germany. This is the first export permit that Maricann has received.
This export permit marks another milestone in the Company’s history and an important first, as we continue to build our Company, globally. Our team of regulatory experts, led by VP of Regulatory Affairs, Dr. Alexandre Sibilev in Canada, continues to add value for Maricann shareholders through this and previous successes, demonstrating a solid track record in moving through regulatory processes.
Ben Ward, CEO of Maricann Group
Our team has expert insight, understanding, and expertise in maintaining our existing licenses, whilst progressing in new geographies with their track record of applied expertise. Export of cannabis from Canada is an important pillar of our near-term strategy, combined with eventual in country production in new geographies, where and when permitted.
The Company is established in Germany, with operations for its two 95% owned subsidiaries, Maricann GmbH (THC cannabis) and Mariplant GmbH (non-THC cannabis) centred at its campus in Ebersbach, Germany (between Leipzig and Dresden). The Company is represented in both Maricann and Mariplant by full time established professionals in the pharmaceutical production and agricultural sectors, respectively.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.
For more information about Maricann, please visit our website at www.maricann.com
The most reliable, fact-based information on Wayland Group Corporation found only on its Investor Dashboard.
Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.